Karyopharm Therapeutics Inc. (KPTI)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue TTM

0 90M 180M 270M Q3 '21: 118.7M Q4 '21: 209.8M Q1 '22: 234.2M Q2 '22: 251.3M Q3 '22: 249.8M Q4 '22: 157.1M Q1 '23: 148.1M Q2 '23: 146M Q3 '23: 145.9M Q4 '23: 146M Q1 '24: 140.5M Q2 '24: 145.7M Q3 '24: 148.4M Q4 '24: 145.2M Q1 '25: 142.1M Q2 '25: 137.3M Q3 '25: 142.5M Q4 '25: 146.1M Q1 '26: 151.1M Q2 '26: 146.6M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Gross Profit TTM

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Income TTM

-210M -140M -70M 0 70M 140M 210M Q3 '21: -182.3M Q4 '21: -98.3M Q1 '22: -80.5M Q2 '22: -74.3M Q3 '22: -61.4M Q4 '22: -142.2M Q1 '23: -138.5M Q2 '23: -125.2M Q3 '23: -125.6M Q4 '23: -129.5M Q1 '24: -132.4M Q2 '24: -130.9M Q3 '24: -126M Q4 '24: -119.4M Q1 '25: -118.9M Q2 '25: -115.2M Q3 '25: -104.1M Q4 '25: -90.7M Q1 '26: -84.2M Q2 '26: -82.3M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Net Income TTM

-240M -160M -80M 0 80M 160M 240M Q3 '21: -206.2M Q4 '21: -124.1M Q1 '22: -108.1M Q2 '22: -103.6M Q3 '22: -88.1M Q4 '22: -165.3M Q1 '23: -158M Q2 '23: -141.6M Q3 '23: -139.8M Q4 '23: -143.1M Q1 '24: -146.3M Q2 '24: -89.9M Q3 '24: -87.5M Q4 '24: -76.4M Q1 '25: -62.5M Q2 '25: -123.6M Q3 '25: -124.6M Q4 '25: -196M Q1 '26: -195M Q2 '26: -224.7M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Cost of Revenue TTM

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Cash Flow TTM

-180M -120M -60M 0 60M 120M 180M Q3 '21: -163.2M Q4 '21: -107.1M Q1 '22: -113.4M Q2 '22: -92.8M Q3 '22: -97.2M Q4 '22: -149.6M Q1 '23: -109.3M Q2 '23: -99.8M Q3 '23: -101M Q4 '23: -92.7M Q1 '24: -117.5M Q2 '24: -130.3M Q3 '24: -120.3M Q4 '24: -127.5M Q1 '25: -122.7M Q2 '25: -102.9M Q3 '25: -89.4M Q4 '25: -75.4M Q1 '26: -59.1M Q2 '26: -65.3M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Free Cash Flow TTM

-210M -140M -70M 0 70M 140M 210M Q1 '21: -168.2M Q2 '21: -183.7M Q3 '21: -163.3M Q4 '21: -107.3M Q1 '22: -113.7M Q2 '22: -93.1M Q3 '22: -97.6M Q4 '22: -149.7M Q1 '23: -109.3M Q2 '23: -99.9M Q3 '23: -101M Q4 '23: -92.7M Q1 '24: -117.7M Q2 '24: -130.5M Q3 '24: -120.5M Q4 '24: -127.6M Q1 '25: -122.8M Q2 '25: -103M Q3 '25: -89.4M Q4 '25: -75.4M Q2 '21 Q1 '22 Q4 '22 Q3 '23 Q2 '24 Q1 '25 Q4 '25

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 40M 80M 120M Q2 '21: 75.2M Q3 '21: 75.5M Q1 '22: 77.6M Q2 '22: 79.7M Q3 '22: 80.2M Q1 '23: 113.5M Q2 '23: 114.2M Q3 '23: 114.4K Q1 '24: 7.7K Q2 '24: 10.3K Q3 '24: 8.3K Q1 '25: 8.5K Q2 '25: 8.6K Q3 '25: 8.7K Q1 '26: 24.7K Q2 '26: 28.9K Q3 '21 Q2 '22 Q1 '23 Q3 '23 Q2 '24 Q1 '25 Q3 '25 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-4.50 -3.00 -1.50 0.00 1.50 3.00 4.50 Q3 '18: -2.97 Q4 '18: -3.13 Q1 '19: -3.44 Q2 '19: -3.55 Q3 '19: -3.43 Q4 '19: -3.23 Q1 '20: -2.92 Q2 '20: -2.84 Q3 '20: -2.90 Q4 '20: -2.72 Q1 '21: -2.71 Q2 '21: -2.79 Q3 '21: -2.75 Q4 '21: -1.65 Q1 '22: -1.41 Q2 '22: -1.32 Q3 '22: -1.08 Q4 '22: -2.02 Q1 '23: -1.79 Q2 '23: -1.46 Q4 '18 Q3 '19 Q2 '20 Q1 '21 Q4 '21 Q3 '22 Q2 '23

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.